Copyright © 2003 by the European Society of Cardiology.
Review article
Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy
a Divisions of Cardiology, Experimental Surgery, and Cardiovascular Surgery, University Hospital, Lausanne, Switzerland
b Ospedale San Giovanni, Bellinzona, Switzerland
c Medizinische Klinik und Poliklinik I, University Hospital Grosshadern, Munich, Germany
* Correspondence to: Dr Giuseppe Vassalli, Cardiologie BH-10, CHUV, 1011 Lausanne, Switzerland. Tel: +41-21-3140076; fax: +41-21-3140076
E-mail address: gvassall{at}hospvd.ch
Received 6 December 2002; revised 7 February 2003; accepted 6 March 2003
Abstract
Graft vasculopathy is an accelerated form of coronary artery disease that occurs in transplanted hearts. Despite major advances in immunosuppression, the prevalence of the disease has remained substantially unchanged during the last two decades. According to the ‘response to injury’ paradigm, graft vasculopathy is the result of a continuous inflammatory response to tissue injury initiated by both alloantigen-dependent and independent stress responses. Experimental evidence suggests that these responses may become self-sustaining, as allograft re-transplantation into the donor strain at a later stage fails to prevent disease progression. Histological evidence of endothelitis and arteritis, in association with intima fibrosis and atherosclerosis, reflects the central role of alloimmunity and inflammation in the development of arterial lesions. Experimental results in gene-targeted mouse models indicate that cellular and humoral immune responses are both involved in the pathogenesis of graft vasculopathy. Circulating antibodies against donor endothelium are found in a significant number of patients, but their pathogenic role is still controversial. Alloantigen-independent factors include donor-transmitted coronary artery disease, surgical trauma, ischaemia-reperfusion injury, viral infections, hyperlipidaemia, hypertension, and glucose intolerance. Recent therapeutic advances include the use of novel immunosuppressive agents such as sirolimus (rapamycin), HMG-CoA reductase inhibitors, calcium channel blockers, and angiotensin converting enzyme inhibitors. Optimal treatment of cardiovascular risk factors remains of paramount importance.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. J. Antunes, M. Biernat, E. Sola, L. Oliveira, D. Prieto, F. Franco, and L. A. Providencia Cardiac allograft systolic function. Is the aetiology (ischaemic or idiopathic) a determinant of ventricular function in the heart transplant patient? Interactive CardioVascular and Thoracic Surgery, August 1, 2008; 7(4): 586 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Schmauss and M. Weis Cardiac Allograft Vasculopathy: Recent Developments Circulation, April 22, 2008; 117(16): 2131 - 2141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Daud, R. D. Yusen, B. F. Meyers, M. M. Chakinala, M. J. Walter, A. A. Aloush, G. A. Patterson, E. P. Trulock, and R. R. Hachem Impact of Immediate Primary Lung Allograft Dysfunction on Bronchiolitis Obliterans Syndrome Am. J. Respir. Crit. Care Med., March 1, 2007; 175(5): 507 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Tu, L. Potena, P. Stepick-Biek, L. Liu, K. Y. Dionis, H. Luikart, W. F. Fearon, T. H. Holmes, C. Chin, J. P. Cooke, et al. T-Cell Immunity to Subclinical Cytomegalovirus Infection Reduces Cardiac Allograft Disease Circulation, October 10, 2006; 114(15): 1608 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Isobe, H. Kosuge, and J.-i. Suzuki T Cell Costimulation in the Development of Cardiac Allograft Vasculopathy: Potential Targets for Therapeutic Interventions Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1447 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tanaka, R.-J. Swijnenburg, F. Gunawan, Y.-A. Cao, Y. Yang, A. D. Caffarelli, J. L. de Bruin, C. H. Contag, and R. C. Robbins In Vivo Visualization of Cardiac Allograft Rejection and Trafficking Passenger Leukocytes Using Bioluminescence Imaging Circulation, August 30, 2005; 112(9_suppl): I-105 - I-110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tanaka, F. Gunawan, R. D. Terry, K. Inagaki, A. D. Caffarelli, G. Hoyt, P. S. Tsao, D. Mochly-Rosen, and R. C. Robbins Inhibition of heart transplant injury and graft coronary artery disease after prolonged organ ischemia by selective protein kinase C regulators J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1160 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Fox and N. A. Nussmeier Does Gender Influence the Likelihood or Types of Complications Following Cardiac Surgery? Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2004; 8(4): 283 - 295. [Abstract] [PDF]
|
|
|
|
|
|
A. A. Fox, S. K. Shernan, and S. C. Body Predictive Genomics of Adverse Events After Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2004; 8(4): 297 - 315. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Tanaka, S. Nakae, R. D. Terry, G. K. Mokhtari, F. Gunawan, L. B. Balsam, H. Kaneda, T. Kofidis, P. S. Tsao, and R. C. Robbins Cardiomyocyte-specific Bcl-2 overexpression attenuates ischemia-reperfusion injury, immune response during acute rejection, and graft coronary artery disease Blood, December 1, 2004; 104(12): 3789 - 3796. [Abstract] [Full Text] [PDF]
|
|